Aurobindo Pharma announced that its wholly owned subsidiary company, Eugia Pharma Specialities, has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Azacitidine for Injection, 100 mg Single-Dose Vial. Azacitidine for Injection, 100 mg Single-Dose Vial, is the bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Vidaza for Injection, 100 mg Single-Dose Vial, of Bristol-Myers Squibb Company. The product is expected to be launched by this month.
The approved product has an estimated market size of around US$ 46 million for the twelve months ending November 2022, according to IQVIA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
